India's Supreme Court favours generic

In an anomalous decision last week, India's highest court ruled that pharmaceutical company Novartis would not be granted renewed IP rights for one of its cancer drugs, Glivec.

The ruling re-ignited an outstanding international debate over the status of pharmaceutical IP protection; how can we provide affordable drugs to developing countries without sacrificing strength (and therefore effectiveness) of the intellectual property system that contributed to their creation?